Table 1.
Table caption
| No. | Age (yr) | Sex | Interval between RCC diagnosis and thyroid metastasis (yr) | Clinical presentation | Size |
Nodular vascularity | Interval between FNA and CNB | Pathologic diagnosis |
||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prior exam (cm) | Interval (mo) | Most recent (cm) | FNA | CNB | Surgical specimen | |||||||
| 1 | 76 | Male | 16 | Palpable mass | - | - | 5.0×2.9×5.5 | + | 0 | Benign | Metastatic | - |
| RCC | ||||||||||||
| 2 | 66 | Male | 14 | Palpable mass | 1.5×0.9×1.6 | 55 | 2.6×1.7×3.5 | ++ | 3 wk | Nondiagnostic | Metastatic | Metastatic |
| RCC | RCC | |||||||||||
| 0.3×0.3×0.5 | 55 | 1.4×1.3×2.6 | + | - | - | - | Metastatic | |||||
| RCC | ||||||||||||
| 3 | 59 | Female | 12 | Palpable mass | - | - | 4.3×2.6×5.1 | ++ | 0 | Atypia of undetermined significance | Metastatic | Metastatic |
| RCC | RCC | |||||||||||
| 4 | 49 | Male | 6 | Palpable mass | 1.0×0.8×1.2 | 34 | 1.7×1.4×4.1 | ++ | 4 wk | Benigna), atypia of undetermined significancea) | Metastatic | |
| RCC | ||||||||||||
| 5 | 62 | Male | 4.5 | Asymptomatic | - | - | 1.2x0.8x1.5 | + | 1 wk | Nondiagnostic | Metastatic | Metastatic |
| RCC | RCC | |||||||||||
| 6 | 51 | Female | 4.5 | Asymptomatic | 2.0x1.0x2.7 | 13 | 2.7x1.4x3.2 | ++ | - | Benign | - | Metastatic |
| RCC | ||||||||||||
| 7 | 49 | Male | 3.5 | Palpable mass | - | - | 4.3x2.0x4.9 | + | - | Metastatic | - | Metastatic |
| RCC | RCC | |||||||||||
| 8 | 66 | Male | 16 | Palpable mass | 5.8x2.7x7.2 | 10 | 5.9x3.3x7.4 | ++ | 10 mo | Benign | Metastatic | Metastatic |
| RCC | RCC | |||||||||||
Age: age at the time of diagnosis of metastatic RCC in the thyroid gland. Size: size of metastatic nodule at the time of diagnosis.
FNA, fine-needle aspiration; CNB, core needle biopsy; RCC, renal cell carcinoma.
a)
FNA was performed twice with a 34-month interval between each FNA.